This study is looking at the long-term safety of patients who have been treated with experimental medicines called RP1, RP2, or RP3. These medicines are being tested in people with different types of cancer, including melanoma (a type of skin cancer), metastatic melanoma (melanoma that has spread to other parts of the body), hepatocellular carcinoma (a type of liver cancer), and other advanced solid tumors (which are cancers that form solid masses in the body). The medicines are given as injections directly into the tumor. The purpose of this study is to check for any health problems that might appear a long time after treatment with these experimental medicines.
People who join this study must have already received at least one dose of RP1, RP2, or RP3 in a previous study and have either finished that study or stopped participating in it. During this study, doctors will watch for specific types of delayed health problems that might be related to the treatment. These include new cancers, new or worsening problems with the nervous system (which controls things like movement and sensation), new or worsening problems with the immune system (which protects the body from disease) or conditions where the immune system attacks the body itself, new blood disorders, new infections related to the treatment, and new infections caused by the herpes virus.
The study will follow patients for several years to collect information about their health and any new medical problems that develop. This helps researchers understand if there are any long-term effects from treatment with these experimental medicines. Patients will be asked to report any new health issues to their doctors, who will record this information as part of the study.



France
Germany
Greece
Poland
Spain